Notes
see Reactions 1591 p3; 803173606
Reference
Medicines and Healthcare products Regulatory Agency (UK). Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia - clarification. Drug Safety Update 10: 4, No. 5, Dec 2016. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/577417/pdf_Dec.pdf
Rights and permissions
About this article
Cite this article
Spironolactone + renin-angiotensin drugs: MHRA clarification. Reactions Weekly 1633, 11 (2017). https://doi.org/10.1007/s40278-017-24282-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-24282-5